Alzheimer's Disease: Diagnosis
The question
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of using (a) PET scans, (b) cerebrospinal fluid testing and (c) other bio-marker led tests to confirm Alzheimer's disease.
Answered by Stephen Kinnock
The Department delivers dementia research through the National Institute for Health and Care Research (NIHR). The NIHR funds a range of research into dementia, for example investing almost £11 million to develop new digital approaches for the early detection and diagnosis of dementia.
The Government’s Dame Barbara Windsor Dementia Goals programme has already invested £13 million into a range of biomarker innovation projects which include biomarker technologies, ranging from an artificial intelligence tool designed to improve the accuracy of blood tests for dementia, to using retinal scans to detect early-onset dementia decades before symptoms. Some of these innovations could support improved diagnosis in the future, if validated for clinical use.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →